Correction to “Synergism of calycosin and bone marrow-derived mesenchymal stem cells to combat podocyte apoptosis to alleviate adriamycin-induced focal segmental glomerulosclerosis”

Abstract

This is an erratum to the published paper entitled “Synergism of calycosin and bone marrow-derived mesenchymal stem cells to combat podocyte apoptosis to alleviate adriamycin-induced focal segmental glomerulosclerosis”. Upon re-examining our original data, we have identified an error in the assembly of Figure 1F, where the glyceraldehyde-3-phosphate dehydrogenase loading control image was incorrectly placed due to a clerical oversight during figure preparation. This does not reflect any issue with the underlying experimental data.

Key Words: Correction; Calycosin; Mesenchymal stem cells; Focal segmental glomerulosclerosis; Apoptosis; Smad3

Core Tip: This is a correction to “Synergism of calycosin and bone marrow-derived mesenchymal stem cells to combat podocyte apoptosis to alleviate adriamycin-induced focal segmental glomerulosclerosis”. Upon re-examining our original data, we identified an error in the assembly of Figure 1F, where the glyceraldehyde-3-phosphate dehydrogenase loading control image was incorrectly placed due to a clerical oversight during figure preparation. As the corresponding author, I am submitting the corrected figure.

TO THE EDITOR

This is a correction to the article “Synergism of calycosin and bone marrow-derived mesenchymal stem cells to combat podocyte apoptosis to alleviate adriamycin-induced focal segmental glomerulosclerosis”, published in the World J Stem Cells 2023; 15: 617-631[1]. Upon re-examining our original data, we have identified an error in the assembly of Figure 1F, where the glyceraldehyde-3-phosphate dehydrogenase loading control image was incorrectly placed due to a clerical oversight during figure preparation. This does not reflect any issue with the underlying experimental data. We have thoroughly reviewed the Supplementary material associated with the original article and confirmed that this error is limited to Figure 1F in the main text; the Supplementary material remain accurate as published. We apologize for the error, and here submit the corrected Figure 1. This correction is being requested to ensure the accuracy of the published data in the original paper. This correction does not impact the conclusion of the manuscript.

Figure 1 Mesenchymal stem cells pretreated with calycosin enhance the protective effect of mesenchymal stem cells on podocyte injury in adriamycin-induced focal segmental glomerulosclerosis mice. A: Mice received adriamycin injections through the tail vein at week 6; were injected with Dulbecco’s modified eagle medium, mesenchymal stem cells (MSCs), calycosin (CA), and MSCs pretreated with CA (MSCs^CA) at week 10; and were sacrificed at week 14; B: Albumin/creatinine ratio in urine (n = 6), ^aP < 0.05, ^bP < 0.001; C: Pathological changes in the kidneys of mice examined by hematoxylin-eosin staining. Typical glomeruli are indicated by black boxes and enlarged in the bottom row. Bar = 50 μm; D: Changes in the kidneys of mice examined by podocin immunofluorescence staining. Glomeruli are indicated by white boxes and enlarged in the bottom row. Bar = 50 μm; E: Relative (podocin/GAPDH) mRNA expression analyzed by real-time quantitative polymerase chain reaction. Data are expressed as the mean ± SD (n = 6). ^aP < 0.05, ^bP < 0.001; F and G: Relative protein levels (podocin/GAPDH) detected by western blot. Data are expressed as the mean ± SD (n = 3). ^aP < 0.05, ^bP < 0.001. NC: Normal control; ADR: Adriamycin; DMEM: Dulbecco’s modified eagle medium; MSCs: Mesenchymal stem cells; CA: Calycosin; MSCs^CA: Mesenchymal stem cells pretreated with calycosin.